Friday, 16 October 2026European Markets

COVIVIO HOTELS And CBO TERRITORIA Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - covivio hotels (covh.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
covivio hotels (covh.pa) €17.30 6.89% 14.02%
cbo territoria (cbot.pa) €3.85 6.27% 7.05%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. covivio hotels (covh.pa)

6.89% forward dividend yield and 14.02% return on equity

covivio hotels specialises in holding lease properties in the hotel industry. société d'investissements immobiliers cotée (siic), real estate partner of leading hotel industry operators, covivio hotels holds a portfolio worth €6.6 billion. covivio hotels is rated bbb+/stable outlook by standard and poor's.

earnings per share

as for profitability, covivio hotels has a trailing twelve months eps of €3.23.

pe ratio

covivio hotels has a trailing twelve months price to earnings ratio of 5.36. meaning, the purchaser of the share is investing €5.36 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.02%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, covivio hotels's stock is considered to be overbought (>=80).

volume

today's last reported volume for covivio hotels is 1754 which is 31.96% below its average volume of 2578.

more news about covivio hotels.

2. cbo territoria (cbot.pa)

6.27% forward dividend yield and 7.05% return on equity

cbo territoria sa engages in the urban planning and development, and property development and investment activities in france. the company develops and sells housings, offices, buildings, retail parks, shopping centers, business premises, and warehouses. it is also involved in the leisure, marketing, and coworking businesses. in addition, the company also owns approximately 3,000 hectares of land in réunion island. cbo territoria sa was founded in 2004 and is headquartered in sainte-marie, france.

earnings per share

as for profitability, cbo territoria has a trailing twelve months eps of €0.41.

pe ratio

cbo territoria has a trailing twelve months price to earnings ratio of 9.39. meaning, the purchaser of the share is investing €9.39 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.05%.

yearly top and bottom value

cbo territoria's stock is valued at €3.85 at 02:30 est, under its 52-week high of €3.92 and way higher than its 52-week low of €3.42.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cbo territoria's stock is considered to be overbought (>=80).

dividend yield

as stated by morningstar, inc., the next dividend payment is on jun 13, 2023, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 6.27%.

volatility

cbo territoria's last week, last month's, and last quarter's current intraday variation average was 0.13%, 0.38%, and 0.47%.

cbo territoria's highest amplitude of average volatility was 0.39% (last week), 0.50% (last month), and 0.47% (last quarter).

more news about cbo territoria.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com